1. Home
  2. OLN vs RAPP Comparison

OLN vs RAPP Comparison

Compare OLN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olin Corporation

OLN

Olin Corporation

HOLD

Current Price

$16.77

Market Cap

2.5B

Sector

Industrials

ML Signal

HOLD

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$40.75

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLN
RAPP
Founded
1892
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.3B
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
OLN
RAPP
Price
$16.77
$40.75
Analyst Decision
Hold
Strong Buy
Analyst Count
13
6
Target Price
$25.23
$48.50
AVG Volume (30 Days)
2.6M
263.9K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
2.92%
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
$6,780,800,000.00
N/A
Revenue This Year
$2.57
N/A
Revenue Next Year
$3.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.68
N/A
52 Week Low
$16.68
$23.75
52 Week High
$30.46
$52.93

Technical Indicators

Market Signals
Indicator
OLN
RAPP
Relative Strength Index (RSI) 37.01 33.60
Support Level $16.73 $38.95
Resistance Level $18.29 $43.99
Average True Range (ATR) 0.62 1.96
MACD 0.07 -0.88
Stochastic Oscillator 7.10 3.81

Price Performance

Historical Comparison
OLN
RAPP

About OLN Olin Corporation

Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: